Chiara Paglino

3.0k total citations · 1 hit paper
46 papers, 2.4k citations indexed

About

Chiara Paglino is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Chiara Paglino has authored 46 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 29 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Chiara Paglino's work include Renal cell carcinoma treatment (30 papers), Renal and related cancers (20 papers) and Cancer Genomics and Diagnostics (10 papers). Chiara Paglino is often cited by papers focused on Renal cell carcinoma treatment (30 papers), Renal and related cancers (20 papers) and Cancer Genomics and Diagnostics (10 papers). Chiara Paglino collaborates with scholars based in Italy, Canada and United States. Chiara Paglino's co-authors include Camillo Porta, Alessandra Mosca, Ilaria Imarisio, Lucia Bonomi, Mara De Amici, Silvana Quaglini, Carlo Ganini, Lucia Sacchi, Gino Roberto Corazza and Remigio Moratti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Kidney International.

In The Last Decade

Chiara Paglino

46 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting PI3K/Akt/mTOR Signaling in Cancer

2014 1.2k citations Camillo Porta, Chiara Paglino et al. profile →

Peers

Countries citing papers authored by Chiara Paglino

Since Specialization

Citations

This map shows the geographic impact of Chiara Paglino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Paglino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Paglino more than expected).

Fields of papers citing papers by Chiara Paglino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiara Paglino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Paglino. The network helps show where Chiara Paglino may publish in the future.

Co-authorship network of co-authors of Chiara Paglino

This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Paglino. A scholar is included among the top collaborators of Chiara Paglino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Paglino. Chiara Paglino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Approccio al trattamento di prima linea del carcinoma renale a cellule chiare metastatico 2015 ·Recenti Progressi in Medicina ·(unknown), (unknown), (unknown), Chiara Paglino, Camillo Porta	1
2	Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis 2015 ·Annals of Oncology ·Franco Nolè, Roberto Iacovelli, Elena Verri, Giuseppe Renne, Chiara Paglino, Matteo Santoni, Maria Cossu Rocca, (unknown), Gaetano Aurilio, Daniela Cullurà, Stefano Cascinu, Camillo Porta	4
3	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 2015 ·Targeted Oncology ·Roberto Iacovelli, Franco Nolè, Elena Verri, Giuseppe Renne, Chiara Paglino, Matteo Santoni, Maria Cossu Rocca, (unknown), Gaetano Aurilio, Daniela Cullurà, Stefano Cascinu, Camillo Porta	147
4	Identification of transcriptionally active HPV infection in formalin-fixed, paraffin-embedded biopsies of oropharyngeal carcinoma 2015 ·Human Pathology ·Patrizia Morbini, Paola Alberizzi, Carmine Tinelli, Chiara Paglino, Giulia Bertino, Patrizia Comoli, Paolo Pedrazzoli, Marco Benazzo	14
5	Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line 2015 ·Expert Opinion on Pharmacotherapy ·Camillo Porta, (unknown), Chiara Paglino	8
6	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature 2014 ·Clinical Genitourinary Cancer ·Vittorio Fusco, Camillo Porta, Giorgia Saia, Chiara Paglino, Giordana Bettini, Matteo Scoletta, (unknown), Paolo Vescovi, Elisabetta Merigo, Re G, Pamela Guglielmini, Olga Di Fede, Giuseppina Campisi, Alberto Bedogni	44
7	Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients 2012 ·Oncology ·Camillo Porta, Chiara Paglino, Ilaria Imarisio, Carlo Ganini, Lucia Sacchi, Silvana Quaglini, (unknown), Mara De Amici	69
8	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY) 2012 ·European Urology ·Sergio Bracarda, Camillo Porta, C. Boni, Armando Santoro, Claudia Mucciarini, Antonio Pazzola, Enrico Cortesi, Donatello Gasparro, Roberto Labianca, Francesco Di Costanzo, Alfredo Falcone, Michela Cinquini, Claudia Caserta, Chiara Paglino, Verena De Angelis	21
9	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science 2012 ·Expert Review of Anticancer Therapy ·Camillo Porta, Roberto Sabbatini, Giuseppe Procopio, Chiara Paglino, Enzo Galligioni, Cinzia Ortega	30
10	Lingual Metastasis from Renal Cell Carcinoma: A Case Report and Literature Review 2012 ·Rare Tumors ·Carlo Ganini, Angioletta Lasagna, (unknown), (unknown), Chiara Paglino, Ilaria Imarisio, Patrizia Morbini, Marco Benazzo, Camillo Porta	14
11	TREATMENT OF METASTATIC RENAL CARCINOMA PATIENTS WITH THE COMBINATION OF GEMCITABINE, CAPECITABINE AND BEVACIZUMAB AT A TERTIARY CANCER CENTRE 2011 ·British Journal of Urology ·Camillo Porta, Chiara Paglino	4
12	Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy 2011 ·BMC Cancer ·Camillo Porta, Chiara Paglino, Ilaria Imarisio, (unknown), Kristina Chen, Maureen P. Neary, Mei Sheng Duh	34
13	Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases 2011 ·British Journal of Urology ·Camillo Porta, Giuseppe Procopio, Giacomo Cartenì, Roberto Sabbatini, Alessandra Bearz, Isabella Chiappino, Enzo Maria Ruggeri, Re G, Riccardo Ricotta, Fable Zustovich, Lorenza Landi, Anna Maria Calcagno, Ilaria Imarisio, Elena Verzoni, Mimma Rizzo, Chiara Paglino, Valentina Guadalupi, Emilio Bajetta	76
14	Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib 2010 ·Kidney International ·Camillo Porta, Chiara Paglino, Mara De Amici, Silvana Quaglini, Lucia Sacchi, Ilaria Imarisio, (unknown)	83
15	Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib 2010 ·World Journal of Hepatology ·Camillo Porta, Chiara Paglino	13
16	Sorafenib tosylate in advanced kidney cancer: past, present and future 2009 ·Anti-Cancer Drugs ·Camillo Porta, Chiara Paglino, Ilaria Imarisio, (unknown)	18
17	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma 2008 ·SHILAP Revista de lepidopterología ·Camillo Porta, Chiara Paglino, Luciano Mutti	1
18	Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma 2007 ·Annals of Oncology ·Camillo Porta, Mara De Amici, Silvana Quaglini, Chiara Paglino, (unknown), (unknown), Remigio Moratti, Gino Roberto Corazza	133
19	Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib 2007 ·Clinical and Experimental Medicine ·Camillo Porta, Chiara Paglino, Ilaria Imarisio, Lucia Bonomi	116
20	Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients 2005 ·Lung Cancer ·Camillo Porta, (unknown), Lucia Bonomi, Ilaria Imarisio, Chiara Paglino, Andrea Sartore‐Bianchi, Luciano Mutti	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact